Biotech and Pharma: Building the European Health Union
The European pharmaceutical and biotechnology field this year is undergoing one of the most significant transformations in several decades. For years, the EU has been encountered with an innovation-access paradox. In other words, the Old Continent was home to first class research, but it was falling behind in market speed and equal patient access. As […]
Putting the Cure in Procurement: The Critical Medicines Act
While some see the agreement on the text of the Critical Medicines Act as a victory for patient safety, a deeper analysis shows a complex industrial change that attempts to balance between relatively high costs of European manufacturing and the uncertain security of global supply chains. The political agreement reached in the early hours of […]
Pharma Package at the Door: Healthy Regulation or the Innovation Virus?
After years in the making, the EU Pharma Package is closer to adoption than ever. In this week’s newsletter, we are breaking down the key consequences of its likely implementation. Pharma Package at the Door: Healthy Regulation or the Innovation Virus? The halls of the EU institutions are filled with chatter about one of the […]